Regnum Corp. (RGMP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regnum Corp. (RGMP) trades at $0.0001. Regnum Corp. is a biotechnology company focused on developing and commercializing therapeutics for rare and infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for RGMP: RGMP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGMP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RGMP: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Regnum Corp. (RGMP) Healthcare & Pipeline Overview
Regnum Corp. is a biotechnology firm specializing in the development of therapeutics for rare and infectious diseases, with a primary focus on Leronlimab (PRO 140), a CCR5 antagonist for HIV treatment. The company operates as a subsidiary of Phoenixus AG, navigating the competitive biotechnology landscape.
What Is the Investment Thesis for RGMP?
Regnum Corp. presents a high-risk, high-reward investment profile, primarily centered on the potential of Leronlimab. The company's success hinges on securing regulatory approvals and demonstrating clinical efficacy across various indications. Key value drivers include successful completion of clinical trials, strategic partnerships, and market acceptance of Leronlimab. Investors should closely monitor clinical trial results, regulatory filings, and competitive developments within the HIV and infectious disease therapeutic landscape. The company's small size and OTC listing contribute to heightened volatility and liquidity risks. As of 2026-03-15, the company's market capitalization is $0.00B, reflecting the speculative nature of the investment.
Based on FMP financials and quantitative analysis
RGMP Key Highlights
Regnum Corp. focuses on developing Leronlimab (PRO 140), a monoclonal antibody CCR5 antagonist, targeting HIV.
- The company operates as a subsidiary of Phoenixus AG.
- Regnum Corp. is based in New York City.
- The company has a market capitalization of $0.00B as of 2026-03-15.
- The company has a P/E ratio of -0.00, reflecting its current lack of profitability.
Who Are RGMP's Competitors?
RGMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGMP's Key Strengths?
Novel therapeutic approach with Leronlimab.
- Potential for expanded indications beyond HIV.
- Focus on unmet medical needs in infectious diseases.
- Subsidiary of Phoenixus AG provides financial backing.
What Are RGMP's Weaknesses?
Limited financial resources.
- Dependence on a single product candidate (Leronlimab).
- Small team size (1 employee).
- OTC listing indicates higher risk.
What Could Drive RGMP Stock Higher?
Clinical trial results for Leronlimab in new indications.
- Potential strategic partnerships or licensing agreements.
- Regulatory filings and approvals in new markets.
- Continued research and development of Leronlimab.
- Efforts to expand market awareness and adoption of Leronlimab.
What Are the Key Risks for RGMP?
Financial-distress signal — its Altman Z-Score of -12.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or negative results.
- Regulatory delays or rejections.
- Competition from established HIV therapies.
- Limited financial resources and dependence on a single product candidate.
- OTC listing indicates higher risk and lower liquidity.
What Are the Growth Opportunities for RGMP?
- Expansion of Leronlimab's Indications: Regnum Corp. has the opportunity to expand the use of Leronlimab beyond HIV. Research into its efficacy in treating other diseases, such as cancer and inflammatory conditions, could open up new markets and revenue streams. Successful clinical trials in these areas could significantly increase the company's value. The market for cancer therapeutics alone is projected to reach $200 billion by 2028, presenting a substantial growth opportunity.
- Strategic Partnerships and Licensing Agreements: Forming strategic partnerships with larger pharmaceutical companies or licensing Leronlimab to other firms could provide Regnum Corp. with access to additional resources and expertise. These partnerships could accelerate the development and commercialization of Leronlimab, increasing its market penetration and revenue potential. Licensing agreements could generate upfront payments and royalties, providing a valuable source of funding.
- Regulatory Approvals in New Markets: Obtaining regulatory approvals for Leronlimab in new geographic markets, such as Europe and Asia, could significantly expand the company's reach and revenue potential. These markets represent a large and growing patient population with unmet medical needs. Successful regulatory filings and approvals would require significant investment and resources, but could yield substantial returns.
- Advancements in Manufacturing and Production: Improving the manufacturing and production processes for Leronlimab could reduce costs and increase efficiency. This could improve the company's profitability and competitiveness. Investing in new technologies and manufacturing facilities could streamline production and ensure a reliable supply of Leronlimab to meet market demand. The global market for biopharmaceutical manufacturing is expected to reach $400 billion by 2027.
- Direct-to-Patient Marketing and Sales: Implementing a direct-to-patient marketing and sales strategy could increase awareness and adoption of Leronlimab. This could involve online advertising, social media campaigns, and patient education programs. By directly engaging with patients and healthcare providers, Regnum Corp. can build brand loyalty and drive sales. The market for direct-to-patient pharmaceutical advertising is growing rapidly, driven by the increasing use of digital channels.
What Threats Does RGMP Face?
- Competition from established HIV therapies.
- Regulatory hurdles and clinical trial failures.
- Patent expirations and generic competition.
- Economic downturn and reduced healthcare spending.
What Are RGMP's Competitive Advantages?
- Patented therapeutic (Leronlimab) provides exclusivity.
- Specialized expertise in monoclonal antibody development.
- Established relationships with regulatory agencies.
- Potential for expanded indications beyond HIV.
What Does RGMP Do?
Regnum Corp., a subsidiary of Phoenixus AG, is a biotechnology company dedicated to the development and commercialization of innovative therapeutics targeting rare and infectious diseases. The company's primary focus is on Leronlimab (PRO 140), a monoclonal antibody designed to block the CCR5 receptor, thereby preventing HIV from entering human cells. Founded with the goal of addressing unmet medical needs in the field of infectious diseases, Regnum Corp. has concentrated its efforts on advancing Leronlimab through clinical trials and seeking regulatory approvals. Based in New York City, Regnum Corp. operates within the highly competitive biotechnology sector, striving to bring novel treatments to market. Leronlimab represents the core of the company's pipeline, with potential applications beyond HIV, including research into its efficacy in other diseases. The company's strategy involves rigorous scientific research, clinical development, and strategic partnerships to maximize the potential of its lead therapeutic. Regnum Corp. aims to establish itself as a key player in the development of therapies for challenging and underserved medical conditions.
What Products and Services Does RGMP Offer?
- Develops therapeutics for rare and infectious diseases.
- Commercializes therapeutics for rare and infectious diseases.
- Focuses on Leronlimab (PRO 140), a monoclonal antibody.
- Leronlimab is a CCR5 antagonist designed to prevent HIV from entering human cells.
- Conducts clinical trials to evaluate the safety and efficacy of Leronlimab.
- Seeks regulatory approvals for Leronlimab in various markets.
How Does RGMP Make Money?
- Develops and patents novel therapeutics.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved therapeutics through sales and marketing efforts.
What Industry Does RGMP Operate In?
Regnum Corp. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for HIV therapeutics is well-established but continues to evolve with the emergence of new drug classes and treatment strategies. Companies like Regnum Corp. face the challenge of differentiating their products and demonstrating superior efficacy and safety compared to existing therapies. The biotechnology industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Regnum Corp.'s focus on Leronlimab positions it within the competitive landscape of HIV and infectious disease therapeutics.
Who Are RGMP's Key Customers?
- Patients with HIV.
- Healthcare providers who treat patients with HIV.
- Hospitals and clinics that administer HIV therapies.
- Pharmaceutical distributors and wholesalers.
Company Profile
Regnum Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Robert J. Stubblefield. RGMP has traded publicly since 2019.
Key Financial Metrics
Return on equity for Regnum Corp. stands at 101.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -90.3%, showing how much profit it generates from its asset base. A current ratio of 0.43 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Regnum Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.34 places it in the distress zone, a signal of elevated financial risk.
RGMP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Regnum Corp.'s future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could drive growth.
- The company has made strategic partnerships recently, which may enhance its market position and expand its reach.
- Market perception is improving, with analysts noting a strong pipeline that could lead to significant advancements in the coming months.
Bear Case
- There is growing concern about regulatory challenges that could impact Regnum Corp.'s operations and profitability.
- Social sentiment shows a segment of the community worried about competition, particularly from established players in the industry.
- Recent earnings reports revealed some operational inefficiencies, raising questions about management's effectiveness in executing business strategies.
- Market perception remains cautious due to uncertainty surrounding future funding, which could limit growth opportunities.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RGMP Latest News
No recent news available for RGMP.
RGMP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGMP.
Price Targets
Wall Street price target analysis for RGMP.
RGMP MoonshotScore
What does this score mean?
The MoonshotScore rates RGMP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert J. Stubblefield
Managing Employee
Robert J. Stubblefield serves as the managing employee of Regnum Corp. Information regarding his detailed career history, education, and previous roles is not available. As the leader of a small team, Stubblefield is responsible for overseeing all aspects of the company's operations, including research and development, clinical trials, and regulatory affairs. His experience in the biotechnology industry is crucial for guiding Regnum Corp. through the complex and competitive landscape of drug development.
Track Record: Due to the limited information available, it is difficult to assess Robert J. Stubblefield's specific achievements and strategic decisions at Regnum Corp. However, as the managing employee, he is responsible for driving the company's efforts to advance Leronlimab through clinical trials and seek regulatory approvals. His leadership will be critical in determining the success of Regnum Corp. and its ability to bring innovative therapies to market.
RGMP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Regnum Corp. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosures.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the potential risks and rewards of investing in the company.
- Consult with a qualified financial advisor.
- Research the company's history and any past legal or regulatory issues.
- Subsidiary of Phoenixus AG.
- Focus on developing therapeutics for unmet medical needs.
- Development of Leronlimab (PRO 140).
- Company is based in New York City.
RGMP Healthcare Stock FAQ
What does Regnum Corp. do?
Regnum Corp. is a biotechnology company focused on developing and commercializing therapeutics for rare and infectious diseases. Its primary focus is on Leronlimab (PRO 140), a monoclonal antibody CCR5 antagonist designed to prevent HIV from entering human cells. The company conducts clinical trials to evaluate the safety and efficacy of Leronlimab and seeks regulatory approvals to bring it to market.
What do analysts say about RGMP stock?
As of 2026-03-15, formal analyst coverage of RGMP is limited, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings and price-to-sales ratios, are not meaningful due to the company's current lack of profitability. Growth considerations center on the successful development and commercialization of Leronlimab, as well as potential expansion into new therapeutic areas.
What are the main risks for RGMP?
The main risks for Regnum Corp. include clinical trial failures, regulatory delays or rejections, competition from established HIV therapies, limited financial resources, and dependence on a single product candidate (Leronlimab). The company's OTC listing indicates higher risk and lower liquidity compared to companies listed on major exchanges. Investors should carefully consider these risks before investing in RGMP.
What are the key factors to evaluate for RGMP?
Evaluate RGMP on fundamentals, analyst consensus, and risk factors. Regnum Corp. presents a high-risk, high-reward investment profile, primarily centered on the potential of Leronlimab. Not financial advice.
How frequently does RGMP data refresh on this page?
RGMP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGMP's recent stock price performance?
Regnum Corp. (RGMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach with Leronlimab. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGMP overvalued or undervalued right now?
Regnum Corp. (RGMP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGMP before investing?
Before investing in Regnum Corp. (RGMP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower liquidity.
- Small team size and dependence on a single product candidate.